Brief Prescribing Information:

Letroze (letrozole) tablets INDICATIONS AND USAGE: Letroze is an aromatase inhibitor indicated for: (1) Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. (2) Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant Tamoxifen therapy. (3) First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer. DOSAGE AND ADMINISTRATION: Letroze tablets are taken orally without regard to meals: Recommended dose: 2.5 mg once daily. Patients with cirrhosis or severe hepatic impairment: 2.5 mg every other day. DOSAGE FORMS AND STRENGTHS: 2.5 milligram tablets. CONTRAINDICATIONS: Women of premenopausal endocrine status, including pregnant women. WARNINGS AND PRECAUTIONS: Decreases in bone mineral density may occur. Consider bone mineral density monitoring. Increases in total cholesterol may occur. Consider cholesterol monitoring. Fatigue, dizziness and somnolence may occur. Exercise caution when operating machinery. ADVERSE REACTIONS: The most common adverse reactions (>20%) were hot flashes, arthralgia; flushing, asthenia, edema, arthralgia, headache, dizziness, hypercholesterolemia, sweating increased, bone pain; and musculoskeletal These highlights do not include all the information needed to use LETROZE safely and effectively. See full prescribing information for LETROZE. M.R.P: 6,000/- PKR

Ref: [16] Extending Aromatase inhibitor Adjuvant Therapy to 10 years. June 5,2016, at nejm.org.